國家衛生研究院 NHRI:Item 3990099045/12766
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12145/12927 (94%)
造访人次 : 911371      在线人数 : 935
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/12766


    题名: Metformin use is associated with a lower risk of inflammatory bowel disease in patients with type 2 diabetes mellitus
    作者: Tseng, CH
    贡献者: National Institute of Environmental Health Sciences
    摘要: AIM: To compare the risk of inflammatory bowel disease (IBD) between ever users and never users of metformin. METHODS: Patients with newly diagnosed type 2 diabetes mellitus from 1999 to 2005 were enrolled from Taiwan's National Health Insurance. A total of 340,211 ever users and 24,478 never users who were free from IBD on January 1, 2006 were followed up until December 31, 2011. Hazard ratios were estimated by Cox regression incorporated with the inverse probability of treatment weighting using propensity score. RESULTS: New-onset IBD was diagnosed in 6466 ever users and 750 never users. The respective incidence rates were 412.0 and 741.3 per 100,000 person-years and the hazard ratio for ever versus never users was 0.55 (95% confidence interval: 0.51-0.60). A dose-response pattern was observed while comparing the tertiles of cumulative duration of metformin therapy to never users. The respective hazard ratios for the first (< 26.0 months), second (26.0-58.3 months) and third (> 58.3 months) tertiles were 1.00 (0.93-1.09), 0.57 (0.52-0.62) and 0.24 (0.22-0.26). While patients treated with oral antidiabetic drugs (OADs) without metformin were treated as a referent group, the hazard ratios for patients treated with OADs with metformin, with insulin without metformin (with/without other OADs) and with insulin and metformin (with/without other OADs) were 0.52 (0.42-0.66), 0.95 (0.76-1.20) and 0.50 (0.40-0.62), respectively. CONCLUSION: A reduced risk of IBD is consistently observed in patients with type 2 diabetes mellitus who have been treated with metformin.
    日期: 2021-01
    關聯: Journal of Crohn's and Colitis. 2021 Jan;15(1):64-73.
    Link to: http://dx.doi.org/10.1093/ecco-jcc/jjaa136
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1873-9946&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000646876300009
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85090064284
    显示于类别:[其他] 期刊論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    PUB32604412.pdf827KbAdobe PDF302检视/开启


    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈